Welcome
Support Centre
13 October 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophrenia
ISRCTN ISRCTN44218911
ClinicalTrials.gov identifier
Public title A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophrenia
Scientific title
Acronym N/A
Serial number at source LA.01.01.0001
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Schizophrenia
Participants - inclusion criteria 1. Written informed consent
2. Diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria
3. Minimum duration of 12 weeks from diagnosis
4. Maximum duration of 20 years from diagnosis
5. Maintained on same neuroleptic drug(s) for 12 weeks and on the same dose for 4 weeks
6. Total Positive and Negative Syndrome Scale (PANSS) score of 50 or more and a positive sub-scale PANSS score of 15 or more
7. Aged 18 - 65 of either sex
8. In-patient or out-patient
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/06/2000
Anticipated end date 01/06/2001
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Four groups were randomly allocated to placebo or 1 g, 2 g or 4 g ethyl-EPA/day on a double blind basis. Treatment duration 12 weeks.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Laxdale Ltd (UK)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11755456
Contact name Dr  Harald  Murck
  Address Laxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
  City/town Stirling
  Zip/Postcode FK7 9JQ
  Country United Kingdom
  Tel +44 (0)1786 476001
  Fax +44 (0)1786 473137
  Email hmurck@laxdale.co.uk
Sponsor Laxdale Ltd (UK)
  Address Kings Park House
Laurelhill Business Park
Polmaise Road
  City/town Stirling
  Zip/Postcode FK7 9JQ
  Country United Kingdom
  Sponsor website: http://www.laxdale.co.uk/
Date applied 01/07/2001
Last edited 07/09/2007
Date ISRCTN assigned 01/07/2001
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central